Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability-Reference-Cited by-同舟云学术

Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability

Published:2018-01-25 Issue:3 Volume:61 Page:1153-1163
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Randolph John T.¹^ORCID,Krueger A. Chris¹,Donner Pamela L.¹,Pratt John K.¹^ORCID,Liu Dachun¹,Motter Christopher E.¹,Rockway Todd W.¹,Tufano Michael D.¹,Wagner Rolf¹^ORCID,Lim Hock B.¹,Beyer Jill M.¹,Mondal Rubina¹,Panchal Neeta S.¹,Colletti Lynn¹,Liu Yaya¹,Koev Gennadiy¹,Kati Warren M.¹,Hernandez Lisa E.¹,Beno David W. A.¹,Longenecker Kenton L.¹,Stewart Kent D.¹,Dumas Emily O.¹,Molla Akhteruzzaman¹,Maring Clarence J.¹

Affiliation:

1. Research and Development, AbbVie Inc., North Chicago, Illinois 60064, United States

Funder

AbbVie

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b01630

Reference22 articles.

1. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

2. Centers for Disease Control and Prevention Web site:www.cdc.gov/hepatitis/statistics/. See press releasehttps://www.cdc.gov/media/releases/2016/p0504-hepc-mortality.html, May 4, 2016 (accessed Oct 18, 2016) .

3. Current race in the development of DAAs (direct-acting antivirals) against HCV

4. Hepatitis C treatment: an incipient therapeutic revolution

5. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sonogashira cross-coupling strategies towards nucleosides and analogues;Carbohydrate Chemistry;2024-07-03

2. Recent advancements in NS5B inhibitors (2011-2021): Structural insights, SAR studies and clinical status;Journal of Molecular Structure;2023-12

3. Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective;European Journal of Medicinal Chemistry;2022-10

4. Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020);European Journal of Medicinal Chemistry;2022-03

5. Structural modification aimed for improving solubility of lead compounds in early phase drug discovery;Bioorganic & Medicinal Chemistry;2022-02